Respiratory Syncytial Virus Vaccines Market

The respiratory syncytial virus vaccines market (excluding COVID-19) is projected to reach USD 1.24 billion by 2030 from USD 1.60 billion in 2025, at a CAGR of -4.9%. The growth of the respiratory syncytial virus  (RSV) vaccines market is driven by several key factors, including rising disease burden, expanding immunization initiatives, regulatory approvals, and increasing product launches.

Several key players in the respiratory syncytial virus (RSV) vaccines market with a strong footprint include GSK (UK), Pfizer Inc. (US), Moderna, Inc. (US), Sanofi (France), AstraZeneca (UK), Merck & Co., Inc. (US), and Bavarian Nordic (Denmark), and Icosavax (US). Companies in the Respiratory Syncytial Virus vaccine market are expanding beyond traditional vaccine production into high-throughput, automated platforms that span advanced antigen preparation, viral vector manufacturing, mRNA synthesis, and specialized reagents for complex biologics and combination RSV vaccine workflows. By adding new production capacity and launching integrated hardware-software ecosystems, they aim to extend their regional presence across Respiratory Syncytial Virus vaccine development programs, from discovery and translational research through clinical trials and public health applications, to support precision immunization strategies against respiratory syncytial virus.

To know about the assumptions considered for the study download the pdf brochure

In February 2024, Pfizer released positive top-line data on the season 2 efficacy of ABRYSVO, a bivalent RSV vaccine, in adults 60 and older.

GSK (UK) is a leading respiratory syncytial virus (RSV) vaccine player, combining advanced viral vector platforms, automated fill-finish workflows, and cutting-edge manufacturing software to enable scalable production of complex vaccines, including its approved Arexvy RSV vaccine and next-generation combination formulations. By integrating new facilities in Barnard Castle, UK, and expanding U.S. capacity in North Carolina, the company positions itself as a one-stop partner for biopharma and public health organizations needing high-volume, reliable RSV vaccine supply to drive adult immunization programs.

Pfizer, Inc. (US) is a leading Respiratory Syncytial Virus (RSV) vaccine player, combining advanced mRNA and protein subunit platforms, automated fill-finish workflows, and cutting-edge manufacturing software to enable scalable production of complex vaccines, including its approved Abrysvo RSV vaccine and next-generation maternal immunization formulations. By integrating new facilities in Kalamazoo, Michigan, and expanding global capacity, the company positions itself as a one-stop partner for biopharma and public health organizations that need a high-volume, reliable RSV vaccine supply to drive maternal and infant immunization programs.

Moderna, Inc. (UK) is a leading player in Respiratory Syncytial Virus (RSV) vaccines, combining advanced mRNA platforms, automated fill-finish workflows, and cutting-edge manufacturing software to enable scalable production of complex vaccines, including its mRNA-1345 RSV vaccine candidate and next-generation combination formulations. By integrating new facilities in Massachusetts and expanding US capacity, the company positions itself as a one-stop partner for biopharma and public health organizations needing high-volume, reliable RSV vaccine supply to drive precision immunization programs across age groups.

Market Ranking

Leading respiratory syncytial virus (RSV) vaccine companies are moving beyond traditional production to high-throughput, automated platforms that include advanced antigen preparation, viral vector manufacturing, mRNA synthesis, and specialized reagents for complex biologics and combination workflows. GSK leverages adjuvant systems and U.S. facility upgrades to drive RSV and shingles innovation. Pfizer pioneers stabilized prefusion protein platforms with multi-site expansions to enable agile response. Moderna harnesses mRNA technology and Norwood expansions to achieve rapid scalability. Sanofi optimizes protein subunit platforms for efficient tech transfer. AstraZeneca streamlines nanoparticle-based vectors through precision manufacturing hubs. These integrated hardware-software ecosystems support discovery-to-deployment, positioning these companies as one-stop partners advancing precision RSV immunization across biopharma and public health.

Related Reports:

Respiratory Syncytial Virus (RSV) Vaccines Market by Technology (Recombinant, Inactivated & Subunit, Others), Type (Monovalent, Multivalent), End User (Pediatric, Adult) & Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com